Tilray Brands concludes the acquisition of three craft breweries and related brands from Molson Coors, expanding its position in the U.S. craft beer market.
Tilray Brands, Inc. (TLRY) closed the most recent trading day at $1.70, making no change from the previous trading session.
Tilray Brands just executed a major bolt-on acquisition of craft beer brands. It also got the licenses it needs for Germany's medicinal marijuana market.
Tilray's financial results have generally been unimpressive. Regulatory challenges make the company's prospects uncertain.
Tilray Brands is buying more beer brands to bolster its beverage portfolio. Its beverage business was the biggest source of revenue for Tilray last quarter.
Tilray Brands is acquiring businesses, working with regulators, and planning ahead. The acquisition of four craft beer breweries will shore up its U.S. operations.
The latest trading day saw Tilray Brands, Inc. (TLRY) settling at $1.89, representing a +1.07% change from its previous close.
Cannabis stocks have erased most of the gains made earlier this year as concerns about regulations continued. The AdvisorShares Pure US Cannabis ETF (MSOS) was trading at $7.08 on Friday, down by over 37% from its highest point this year.
The Canadian pot purveyor was awarded a new cultivation license in a large European nation. The company's net revenue from sales outside Canada rose 22% in its most recent fiscal year.
Tilray has been growing its business outside of just cannabis over the years. Surprisingly, it is now one of the largest craft brewers in the U.S. Stronger margins in the alcohol business are helping Tilray's financials.
Tilray's craft beer acquisitions are driving sales higher. Management expects continued revenue growth in fiscal 2025.
Tilray reported strong revenue growth in FQ4, but most of it was not organic, mainly driven by acquisitions in the Beverage Alcohol sector. Despite acquisitions, non-beverage segments saw a decline in non-wholesale sales, raising concerns about the company's ability to manage a far-flung business effectively. The company forecast limited organic growth for Tilray in FY25, making TLRY stock expensive trading at 17x adjusted EBITDA and a history of missing financial targets.